Volume 8, Number 2—February 2002
Perspective
Traditional and Molecular Techniques for the Study of Emerging Bacterial Diseases: One Laboratory’s Perspective
Pierre Houpikian and Didier Raoult
Table 2
Key issues for isolating main emerging bacteria
| Medium |
Conditions for incubation |
||||||
|---|---|---|---|---|---|---|---|
| Group | Axenic specific medium | Living system (embryonated egg, cell line) | Low temperature (<37°C) | O2 and CO2 conditions | Extended incubation | ||
| Alpha1 Proteo- bacteriae | Ehrlichia sp. Rickettsia sp. Chlamydia sp. | ELB agent (“Rickettsia felis”) (28°C) | Ehrlichia sp. Rickettsia sp. | ||||
| Alpha2 Proteo- bacteriae | Afipia sp. | Afipia sp. Bartonella sp. | Bartonella bacilliformis (28°C) | Bartonella sp. | |||
| Spirochetae | Borrelia sp. | Treponema pallidum | |||||
| Delta-Xi Proteo- bacteriae | Campylobacter sp. (microaerophilic) Helicobacter sp. (microaerophilic) | Helicobacter pylori | |||||
| Gamma Proteo- bacteriae | Legionella sp. | Legionella sp. | Yersinia pestis | ||||
| Mycobacteria | Mycobacterium sp. | Mycobacterium leprae | Mycobacterium malmoense (microaerophilic) | Mycobacterium sp. | |||
| Mycoplasmas | Mycoplasma sp. | Mycoplasma fermentans | |||||
| Gram-positive bacteria | Tropheryma whipplei | Clostridium difficile (anaerobic) | Tropheryma whipplei | ||||
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.